Premier Alternatives

Elixirgen Therapeutics

Baltimore, MD · Founded 2012 · Privately Held (backing)

Developer of stem cell therapies designed for treating syndrome and Alzheimer's diseases through regenerative and rejuvenating medicines. Elixirgen Therapeutics is based in Baltimore, MD and was founded in 2012. Its last reported valuation was $67 million in Nov 2023. It has raised $29.1 million across 8 recorded rounds; the latest was a $4 million seed round in Oct 2025.

Last reported valuation
$67.0M
Nov 2026
Priced at
—
Total raised
$29.1M
Last round
Seed Round
Oct 2025

Elixirgen Therapeutics key facts

as of Nov 2026
  • Developer of stem cell therapies designed for treating syndrome and Alzheimer's diseases through regenerative and rejuvenating medicines.
  • Elixirgen Therapeutics is valued at approximately $67.0M as of Nov 2026 (last reported valuation).
  • It has raised $29.1M across 8 recorded rounds; the latest was Seed Round ($4.0M) in Oct 2025.
  • Notable investors include The University of Tokyo Edge Capital, Sunovion Pharmaceuticals.
  • Elixirgen Therapeutics has filed 9 Form Ds with the SEC since 2018, most recently Nov 2025 ($4.0M sold to 1 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$67.0M

Elixirgen Therapeutics's last reported valuation, Nov 2023. Nothing priced has surfaced since.

set by last reported valuationas of Nov 2026question about this number?

Elixirgen Therapeutics funding rounds

8 rounds
Oct 2025Seed Round$4.0MSEC filing▮
Mar 2025Seed Round$3.6MSEC filing▮
Jan 2025Seed Round$600KSEC filing▮
Nov 2023Early Stage VC$7.0MSEC filing▮
Sep 2022Debt$5.0MSEC filing▮

Elixirgen Therapeutics valuation

Elixirgen Therapeutics's last reported valuation was $67 million in Nov 2023. No priced round, secondary trade or fund mark has surfaced since.

How much has Elixirgen Therapeutics raised?

Elixirgen Therapeutics has raised $29.1 million across 8 recorded rounds since 2018. The largest was a $7 million early-stage round in Nov 2023; the most recent was a $4 million seed round in Oct 2025.

Elixirgen Therapeutics has filed 9 Form Ds with the SEC since 2018, most recently in Nov 2025 ($4 million sold to 1 investor).

Elixirgen Therapeutics investors

2 investors are on record for Elixirgen Therapeutics, including The University of Tokyo Edge Capital and Sunovion Pharmaceuticals. The seed round in Oct 2025 drew 1 investor.

About Elixirgen Therapeutics

Developer of stem cell therapies designed for treating syndrome and Alzheimer's diseases through regenerative and rejuvenating medicines. The company's services focus on developing therapeutics from protein-based cells that utilize chromosomal features for increasing body immunity, screening DNA structures and eliminating drug-resistant bacteria and viruses, enabling medical researchers to get protein-cell-based therapies for curing chronic telomere diseases.

Sector
Healthcare
HQ
Baltimore, MD, United States
Founded
2012
Employees
14
Ownership
Privately Held (backing)

Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.